As filed with the Securities and Exchange Commission on October 5, 2023
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-8
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
MIRATI THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
Delaware | 46-2693615 | |
(State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification No.) |
3545 Cray Court
San Diego, California 92121
(858) 332-3410
(Address of Principal Executive Offices)
Mirati Therapeutics, Inc. Inducement Plan
(Full title of the plan)
Charles M. Baum, M.D., Ph.D.
Interim Chief Executive Officer
Mirati Therapeutics, Inc.
3545 Cray Court
San Diego, California 92121
(858) 332-3410
(Name, address, including zip code, and telephone number, including area code, of agent for service)
Copies to:
Thomas A. Coll, Esq.
Cooley LLP
10265 Science Center Drive
San Diego, California 92121
Tel: (858) 550-6000
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):
Large Accelerated filer | ☒ | Accelerated filer | ☐ | |||
Non-accelerated filer | ☐ | Smaller reporting company | ☐ | |||
Emerging growth company | ☐ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐
INCORPORATION OF DOCUMENTS BY REFERENCE.
This Registration Statement is being filed for the purpose of increasing the number of securities of the same class as other securities for which a Registration Statement of the Registrant on Form S-8 relating to the same employee benefit plan is effective.
The Registrant previously registered shares of its Common Stock for issuance under the Mirati Therapeutics, Inc. Inducement Plan under Registration Statements on Form S-8 filed with the Securities and Exchange Commission on December 31, 2019 (File No. 333-235765) and on July 15, 2022 (File No. 333-266178). Pursuant to General Instruction E to Form S-8, this Registration Statement hereby incorporates by reference the contents of the Registration Statements referenced above.
ITEM 8. EXHIBITS.
Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of San Diego, State of California, on October 5, 2023.
MIRATI THERAPEUTICS, INC. | ||
By: | /s/ Charles M. Baum | |
Charles M. Baum, M.D., Ph.D. | ||
Interim Chief Executive Officer |
POWER OF ATTORNEY
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Charles M. Baum and Aaron Ondrey, and each of them, as his or her true and lawful attorneys-in-fact and agents, each with full power of substitution, for him or her and in his or her name, place or stead, in any and all capacities, to sign any and all amendments to this Registration Statement (including post-effective amendments), and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or either of them, or their or his substitutes or substitute, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the date indicated.
Signature | Title | Date | ||
/s/ CHARLES M. BAUM | President, Founder, Interim Chief Executive Officer, Head of Research and Development and Member of the Board of Directors | October 4, 2023 | ||
Charles M. Baum, M.D., Ph.D. | (Principal Executive Officer) | |||
/s/ AARON ONDREY | Interim Chief Financial Officer | October 4, 2023 | ||
Aaron Ondrey | (Principal Financial Officer) | |||
/s/ FAHEEM HASNAIN | Chairman of the Board of Directors | October 4, 2023 | ||
Faheem Hasnain | ||||
/s/ BRUCE L.A. CARTER | Member of the Board of Directors | October 4, 2023 | ||
Bruce L.A. Carter, Ph.D. | ||||
/s/ JULIE CHERRINGTON | Member of the Board of Directors | October 4, 2023 | ||
Julie Cherrington, Ph.D. | ||||
/s/ AARON DAVIS | Member of the Board of Directors | October 4, 2023 | ||
Aaron Davis |
/s/ CAROL G. GALLAGHER | Member of the Board of Directors | October 4, 2023 | ||
Carol G. Gallagher, Pharm. D. | ||||
/s/ CRAIG JOHNSON | Member of the Board of Directors | October 4, 2023 | ||
Craig Johnson | ||||
/s/ MAYA MARTINEZ-DAVIS | Member of the Board of Directors | October 4, 2023 | ||
Maya Martinez-Davis | ||||
/s/ SHALINI SHARP | Member of the Board of Directors | October 4, 2023 | ||
Shalini Sharp |